Similar results were obtained by Dixon et al., who reported that, while anti-TIGIT monotherapy did cause a small delay in murine colon carcinoma tumor growth, its combination with anti-PD-1 therapy resulted in complete tumor regression in all mice [74]. Here, TIGIT is linked to colon carcinoma.